Engraftment of a surrogate antigen onto tumor cell surface via pHLIP peptide to universally target CAR-T cell therapy to solid tumors
Cancer Letters · 2025
DOI: 10.1016/j.canlet.2024.217319 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Yan-Ting Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology and Biochemistry, University of Houston, Houston, TX, 77204, USA; Coriell Institute for Medical Research, 403 Haddon Ave, Camde…. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Antigens, Neoplasm, Xenograft Model Antitumor Assays. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Cancer Prevention and Research Institute of Texas, National Institutes of Health.
Abstract (Originalsprache)
CAR-T cells and monoclonal antibodies (mAbs) are immunotherapeutics that have shown efficacies against certain malignancies. However, their broad application is hindered by the scarcity of tumor-associated antigens on tumor cell surfaces. Previous investigations unveiled the unique capacity of pH-low insertion peptide (pHLIP) to anchor to plasma membranes under acidic conditions. Considering that an acidic tumor microenvironment is a hallmark of solid tumors, we engineered a novel peptide, Myc-pHLIP, by tethering a surrogate epitope tag, the c-Myc-tag, to pHLIP. We evaluated the efficiency of Myc-pHLIP in inserting the artificial c-Myc-tag onto the plasma membrane of malignant cells and determined if this engraftment could convert it into a therapeutic target for CAR-T cells or mAbs. Our in vitro experiments demonstrated that incubating Myc-pHLIP with tumor cells in acidic media triggered significant killing by either Myc-targeted CAR-T cells (Myc-CAR-T), or by an anti-Myc mAb in the presence of NK cells. In vivo studies demonstrated substantial antitumor effects with sequential administration of Myc-pHLIP followed by either Myc-CAR-T or Myc-mAb. These findings establish that Myc-pHLIP has the potential to act as a universal surrogate tumor antigen capable of directing CAR-T cells or mAbs to treat any solid tumors by concurrently targeting both malignant and stromal cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biology and Biochemistry, University of Houston, Houston, TX, 77204, USA; Coriell Institute for Medical Research, 403 Haddon Ave, Camden, NJ, 08103, USA; Department Biomedical Sciences, Cooper Medical Scho…
- Department of Biology and Biochemistry, University of Houston, Houston, TX, 77204, USA.
- Department of Biology and Biochemistry, University of Houston, Houston, TX, 77204, USA. Electronic address: shaunzhang@uh.edu.
Förderung
- NCI NIH HHS
- Cancer Prevention and Research Institute of Texas
- National Institutes of Health
- University of Houston
Zitieren
APA
Zhang, Y. T., Fu, X., Ting Lim, J. J., & Zhang, S. X. (2025). Engraftment of a surrogate antigen onto tumor cell surface via pHLIP peptide to universally target CAR-T cell therapy to solid tumors. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.217319
Vancouver
Zhang YT, Fu X, Ting Lim JJ, Zhang SX. Engraftment of a surrogate antigen onto tumor cell surface via pHLIP peptide to universally target CAR-T cell therapy to solid tumors. Cancer Letters. 2025. doi:10.1016/j.canlet.2024.217319
BibTeX
@article{Zhang2025,
author = {Zhang, Yan-Ting and Fu, Xinping and Ting Lim, Jane Jing and Zhang, Shaun Xiaoliu},
title = {Engraftment of a surrogate antigen onto tumor cell surface via pHLIP peptide to universally target CAR-T cell therapy to solid tumors},
journal = {Cancer Letters},
year = {2025},
doi = {10.1016/j.canlet.2024.217319}
}
EUVIMED